Upper gastrointestinal safety of oral bisphosphonate in hospitalized patients

ConclusionThe incidence of adverse reaction was similar to that reported in community trials. The administration of oral bisphosphonate in hospitalized patients does not represent an additional risk for upper gastrointestinal adverse events. Treatment should be optimized during the hospital stay to improve the pharmacological management of osteoporosis.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research